

May 21, 2025

Company name	Nihon Chouzai Co., Ltd.
Company representative	Naoto Kasai, President and CEO
Securities code	3341; Tokyo Stock Exchange Prime Market
Contacts	Takuya Sakurai, General Manager of Group Corporate Planning Department (Phone: +81-3-6810-0800)

(Corrections / Corrections of Numerical Data)

Partial Corrections of “Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Japan GAAP)” and “Results of Operations for the Fiscal Year Ending March 31, 2025”

We have made some corrections to the “Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Japan GAAP)” announced on April 30, 2025 and to the “Results of Operations for the Fiscal Year Ending March 31, 2025” announced on May 14, 2025.

1. Reason for corrections

Following the submission of the “Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Japan GAAP),” it has been discovered that there are errors in the EBITDA figures for the consolidated forecast for the fiscal year ending March 2026 in the Summary Information, and for the content of the FY3/26 Consolidated Forecast and FY3/26 Business Segment Forecast in the “Results of Operations for the Fiscal Year Ending March 31, 2025”. Therefore, we have made the necessary corrections.

2. Corrections (Corrections are underlined)

(1) Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Japan GAAP)

Summary Information

3. Consolidated Forecast for the Fiscal Year Ending March 31, 2026 (April 1, 2025 – March 31, 2026)

(Before Correction)

(Percentages represent year-on-year changes)

	Net sales		EBITDA		Operating profit		Ordinary profit		Profit attributable to owners of parent		Net income per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	
First half	184,200	4.9	<u>8,200</u>	<u>63.9</u>	3,000	609.1	2,000	158.8	900	—	30.12
Full year	372,800	3.4	<u>19,500</u>	<u>23.0</u>	8,000	28.2	6,900	(0.2)	3,500	151.6	117.15

(After Correction)

(Percentages represent year-on-year changes)

	Net sales		EBITDA		Operating profit		Ordinary profit		Profit attributable to owners of parent		Net income per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	184,200	4.9	<u>7,400</u>	<u>47.9</u>	3,000	609.1	2,000	158.8	900	—	30.12
Full year	372,800	3.4	<u>17,900</u>	<u>12.9</u>	8,000	28.2	6,900	(0.2)	3,500	151.6	117.15

(2) Results of Operations for the Fiscal Year Ending March 31, 2025

Page 13

(Before Correction)

1

Financial Highlights

NIHON CHOUZAI Co., Ltd.

FY3/26 Consolidated Forecast

Anticipate higher sales and profit backed by an increase in prescription volume in the Dispensing Pharmacy Business and earnings recovery in the Pharmaceutical Manufacturing and Sales Business.

(Millions of yen)	FY3/23 Results	FY3/24 Results	FY3/25 Results	FY3/26 Forecast	YoY change	YoY growth rate
Net sales	313,318	340,310	360,512	372,800	12,287	3.4%
Cost of sales	259,674	283,073	303,147	313,400	10,252	3.4%
Gross profit	53,643	57,236	57,365	59,300	1,934	3.4%
% to sales	17.1%	16.8%	15.9%	15.9%	(0.0pt)	-
SG&A expenses	46,057	48,093	51,125	51,200	74	0.1%
% to sales	14.7%	14.1%	14.2%	13.7%	(0.4pt)	-
Consumption taxes	20,219	22,292	23,909	25,500	1,590	6.7%
R&D expenses	3,065	2,765	3,133	3,300	166	5.3%
Operating profit	7,586	9,142	6,239	8,000	1,760	28.2%
% to sales	2.4%	2.7%	1.7%	2.1%	0.4pt	-
Ordinary profit	7,682	9,439	6,915	6,900	(15)	(0.2%)
% to sales	2.5%	2.8%	1.9%	1.9%	(0.1pt)	-
Profit attributable to owners of parent	4,458	2,553	1,391	3,500	2,108	151.6%
% to sales	1.4%	0.8%	0.4%	0.9%	0.6pt	-
Net income per share (Yen) <small>note</small>	148.92	85.35	46.54	117.15	70.62	151.8%
EBITDA	16,337	18,251	15,856	19,500	3,643	23.0%
Dividend per share (Yen) <small>note</small>	25.00	25.00	25.00	25.00	-	-

©2025 NIHON CHOUZAI Co., Ltd. All rights reserved.

Figures in the plan are rounded down to the nearest 100 million yen.

13

(After Correction)

1

Financial Highlights

NIHON CHOUZAI Co., Ltd.

FY3/26 Consolidated Forecast

Anticipate higher sales and profit backed by an increase in prescription volume in the Dispensing Pharmacy Business and earnings recovery in the Pharmaceutical Manufacturing and Sales Business.

(Millions of yen)	FY3/23 Results	FY3/24 Results	FY3/25 Results	FY3/26 Forecast	YoY change	YoY growth rate
Net sales	313,318	340,310	360,512	372,800	12,287	3.4%
Cost of sales	259,674	283,073	303,147	313,400	10,252	3.4%
Gross profit	53,643	57,236	57,365	59,300	1,934	3.4%
% to sales	17.1%	16.8%	15.9%	15.9%	(0.0pt)	-
SG&A expenses	46,057	48,093	51,125	51,200	74	0.1%
% to sales	14.7%	14.1%	14.2%	13.7%	(0.4pt)	-
Consumption taxes	20,219	22,292	23,909	25,500	1,590	6.7%
R&D expenses	3,065	2,765	3,133	3,300	166	5.3%
Operating profit	7,586	9,142	6,239	8,000	1,760	28.2%
% to sales	2.4%	2.7%	1.7%	2.1%	0.4pt	-
Ordinary profit	7,682	9,439	6,915	6,900	(15)	(0.2%)
% to sales	2.5%	2.8%	1.9%	1.9%	(0.1pt)	-
Profit attributable to owners of parent	4,458	2,553	1,391	3,500	2,108	151.6%
% to sales	1.4%	0.8%	0.4%	0.9%	0.6pt	-
Net income per share (Yen) <small>note</small>	148.92	85.35	46.54	117.15	70.62	151.8%
EBITDA	16,337	18,251	15,856	17,900	2,043	12.9%
Dividend per share (Yen) <small>note</small>	25.00	25.00	25.00	25.00	-	-

©2025 NIHON CHOUZAI Co., Ltd. All rights reserved.

Figures in the plan are rounded down to the nearest 100 million yen.
13

(Before Correction)

1

Financial Highlights

NIHON CHOUZAI Co., Ltd.

FY3/26 Business Segment Forecast

	(Millions of yen)	FY3/23 Results	FY3/24 Results	FY3/25 Results	26/3 Forecast	YoY change	YoY growth rate
Dispensing pharmacy business	Net sales	280,164	302,805	321,951	331,700	9,748	3.0%
	Gross profit	45,041	46,993	47,219	46,300	(919)	(1.9%)
	% to sales	16.1%	15.5%	14.7%	14.0%	(0.7pt)	—
	Operating profit	14,666	15,189	13,446	12,400	(1,046)	(7.8%)
	% to sales	5.2%	5.0%	4.2%	3.7%	(0.4pt)	—
	EBITDA	19,314	19,828	18,652	19,600	947	5.1%
Pharmaceutical manufacturing and sales business	Net sales	38,575	40,446	40,156	43,100	2,943	7.3%
	Gross profit	3,745	4,941	4,285	6,900	2,614	61.0%
	% to sales	9.7%	12.2%	10.7%	16.0%	5.3pt	—
	Operating profit	(1,392)	250	(630)	1,700	2,330	—
	% to sales	—	0.6%	—	3.9%	—	—
	EBITDA	2,130	3,773	2,869	5,100	2,230	77.7%
Medical professional staffing and placement business	Net sales	8,063	9,984	11,365	11,600	234	2.1%
	Gross profit	4,781	5,393	5,879	6,100	220	3.8%
	% to sales	59.3%	54.0%	51.7%	52.6%	0.9pt	—
	Operating profit	758	937	937	1,000	62	6.7%
	% to sales	9.4%	9.4%	8.2%	8.6%	0.4pt	—
	EBITDA	936	1,103	1,089	1,100	10	1.0%

©2025 NIHON CHOUZAI Co., Ltd. All rights reserved.

*Figures in the plan are rounded down to the nearest 100 million yen.

15

15

(After Correction)

1

Financial Highlights

NIHON CHOUZAI Co., Ltd.

FY3/26 Business Segment Forecast

	(Millions of yen)	FY3/23 Results	FY3/24 Results	FY3/25 Results	26/3 Forecast	YoY change	YoY growth rate
Dispensing pharmacy business	Net sales	280,164	302,805	321,951	331,700	9,748	3.0%
	Gross profit	45,041	46,993	47,219	46,300	(919)	(1.9%)
	% to sales	16.1%	15.5%	14.7%	14.0%	(0.7pt)	—
	Operating profit	14,666	15,189	13,446	12,400	(1,046)	(7.8%)
	% to sales	5.2%	5.0%	4.2%	3.7%	(0.4pt)	—
	EBITDA	19,314	19,828	18,652	18,100	(552)	(3.0%)
Pharmaceutical manufacturing and sales business	Net sales	38,575	40,446	40,156	43,100	2,943	7.3%
	Gross profit	3,745	4,941	4,285	6,900	2,614	61.0%
	% to sales	9.7%	12.2%	10.7%	16.0%	5.3pt	—
	Operating profit	(1,392)	250	(630)	1,700	2,330	—
	% to sales	—	0.6%	—	3.9%	—	—
	EBITDA	2,130	3,773	2,869	5,100	2,230	77.7%
Medical professional staffing and placement business	Net sales	8,063	9,984	11,365	11,600	234	2.1%
	Gross profit	4,781	5,393	5,879	6,100	220	3.8%
	% to sales	59.3%	54.0%	51.7%	52.6%	0.9pt	—
	Operating profit	758	937	937	1,000	62	6.7%
	% to sales	9.4%	9.4%	8.2%	8.6%	0.4pt	—
	EBITDA	936	1,103	1,089	1,100	10	1.0%

©2025 NIHON CHOUZAI Co., Ltd. All rights reserved.

*Figures in the plan are rounded down to the nearest 100 million yen.

15

15

End